Skip to main content
Premium Trial:

Request an Annual Quote

Plexera Inks Option for Protein Array Technology from Harvard Spinout

NEW YORK (GenomeWeb News) – Lumera’s life sciences subsidiary Plexera today said it has signed an option agreement for protein array technology from Harvard University spinout Auguron Biosciences.
The company said it will use Auguron’s Nucleic Acid Programmable Protein Array (NAPPA), which was developed at the Harvard Institute of Proteomics, to generate functional proteins on high density microchips from surface printed DNA.
The deal builds on a longstanding collaboration between Lumera and the Harvard Institute of Proteomics related to the NAPPA technology. Auguron was formed early last year to commercialize technology developed in the institute.
The option agreement grants Plexera access for one year and includes the potential for another one-year extension. During that period, Plexera said it will test and develop the NAPPA technology as a potential content source for its Plexera Kx Array platform in collaboration with Auguron and with other partners, which the company did not name.
The agreement also gives Plexera the option to negotiate an exclusive license for NAPPA.
"By printing DNA and expressing proteins in-situ, NAPPA skips the expense, time, yield and activity consuming steps associated with conventional printed protein arrays,” Auguron CEO Jim Richey said in a statement.
Financial terms of the license were not disclosed.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.